Phio Pharmaceuticals
PHIO
12 hedge funds and large institutions have $445K invested in Phio Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 1 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
9% more funds holding
Funds holding: 11 → 12 (+1)
0.59% less ownership
Funds ownership: 2.02% → 1.44% (-0.59%)
44% less capital invested
Capital invested by funds: $798K → $445K (-$353K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$35.1K |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$23K |
| 3 |
Renaissance Technologies
New York
|
+$19.4K |
| 4 |
Citigroup
New York
|
+$2.12K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.58K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$64.8K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.64K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $236K | -$1.64K | -79 | -0.5% |
|
|
2
Bank of Montreal
Toronto,
Ontario, Canada
| $43.2K | +$23K | +1,111 | +100% |
|
3
Vanguard Group
Malvern,
Pennsylvania
| $36.8K | – | – | – |
|
|
BCM
4
Bridgeway Capital Management
Houston,
Texas
| $35.2K | – | – | – |
|
|
5
Renaissance Technologies
New York
| $30K | +$19.4K | +937 | +75% |
|
|
6
Geode Capital Management
Boston,
Massachusetts
| $22.8K | +$35.1K | +1,692 | New |
|
7
Cambridge Investment Research Advisors
Fairfield,
Iowa
| $21K | – | – | – |
|
8
Cetera Investment Advisers
Schaumburg,
Illinois
| $16.1K | – | – | – |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $3.03K | +$1.58K | +76 | +52% |
|
|
10
Citigroup
New York
| $1.38K | +$2.12K | +102 | New |
|
11
Morgan Stanley
New York
| $189 | – | – | – |
|
12
Wells Fargo
San Francisco,
California
| $24 | +$21 | +1 | +100% |
|
13
JP Morgan Chase
New York
| $6 | – | – | – |
|
14
BlackRock
New York
| $2 | – | – | – |
|
|
AFM
15
Anson Funds Management
Dallas,
Texas
| – | -$64.8K | -2,508 | Closed |
|
PHIO Hedge Fund Activity: Q3 2023 in Review
12 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q3 2023, worth a combined $445K — down 44% from $798K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new PHIO positions and 1 closed out — a net gain of 1 holder — while 4 added to existing stakes and 1 trimmed.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $35.1K. The largest seller was Anson Funds Management, exiting entirely with an estimated $64.8K sold.
- 12 institutional investors held Phio Pharmaceuticals (PHIO) as of Q3 2023, up from 11 in Q2 2023.
- Funds reported $445K of Phio Pharmaceuticals stock for Q3 2023, down 44% quarter-over-quarter.
- 2 funds opened new Phio Pharmaceuticals positions in Q3 2023 and 1 closed out, a net change of +1 holder.
- The largest Phio Pharmaceuticals buyer in Q3 2023 was Geode Capital Management, an estimated $35.1K added.
- The largest Phio Pharmaceuticals seller in Q3 2023 was Anson Funds Management, an estimated $64.8K sold.
Based on aggregated 13F filings for Q3 2023.